TOI reports Q4 revenue $86M (+20.1% YoY), net loss widens to $18.8M

Oncology Institute, Inc.

Q4 2023 revenue $86M (+20.1% YoY); gross profit $14M (-8.0% YoY).
Net loss $18.8M (vs $11.0M loss in Q4 2022); diluted EPS -$0.21.
Adjusted EBITDA -$6.3M (vs -$4.6M in prior year quarter).
Operational: remediated material weakness, signed full-risk contract in South Florida, launched CA pharmacy with 1,300 specialty fills.
Ended 2023 with 69 clinics, 119 providers; cash $83M. 2024 outlook mentioned but not detailed.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oncology Institute, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $86 million, net income $18.8 million, EPS $(0.21).

Period: fourth quarter and fiscal year ended December 31, 2023
Revenue: $86 million
Net income: $18.8 million
EPS: $(0.21)
Result: reported results

Exact text from the filing

Officer. • Hired 7 new providers in the quarter and ended the year with 69 clinics and 119 employed providers. Fourth Quarter 2023 Financial Highlights • Consolidated revenue of $86 million, an increase of 20.1% compared to the prior year quarter • Gross profit of $14 million, a decrease of 8.0% compared to the prior year quarter • Net loss of $18.8 million compared

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-013295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.